| Fresenius Medical Care AG & Co. KGaA (DE0005785802) | |||
48,80 EURStand (close): 01.07.25 |
 |
||
Nachrichten |
||
| Datum / Uhrzeit | Titel | Bewertung |
| 25.06.25 15:15:00 | Tajila Mullahkhel Featured in In-Depth Interview Exploring Her Journey from Afghanistan to Engineering Innovator |  |
| Tajila Mullahkhel Shares Her Inspiring Journey of Resilience, Innovation, and Cultural Identity SALT LAKE CITY, UT / ACCESS Newswire / June 25, 2025 / Tajila Mullahkhel, a self-employed chemical engineer, educator, and entrepreneur, is the subject of a newly published feature interview. The powerful and intimate conversation explores her remarkable journey from her early life in Afghanistan and Pakistan to building a dynamic career and life in the United States. The online feature highlights Tajila's multifaceted accomplishments, from her biomimetics research and engineering work at Fresenius Medical Care to her role as a Pashto language instructor and mother. It also delves into her philosophy on healthy living, quiet philanthropy, and the cultural bridges she continues to build through education and entrepreneurship. "Tajila's story is a testament to resilience, intellect, and cultural pride," said the editors behind the piece. "Her ability to navigate complex scientific fields while staying rooted in family, faith, and identity is both rare and inspiring." In the interview, Tajila opens up about how motherhood fuels her professional purpose, how nature inspires her problem-solving, and why she values giving back without recognition. The feature is now available for reading at the website here. About Tajila Mullahkhel: Born in Afghanistan, raised in Pakistan, and educated in the United States, Tajila Mullahkhel is a chemical engineer with deep expertise in biomimetics research, sustaining engineering, and project management. She is passionate about fostering a healthy lifestyle, cultural education, and community empowerment through quiet philanthropy and family-centered living. Contact: info@tajilamullahkhel.com SOURCE: Tajila Mullahkhel View the original press release on ACCESS Newswire View Comments |
||
| 25.06.25 13:40:02 | Are You a Value Investor? This 1 Stock Could Be the Perfect Pick | |
| Taking full advantage of the stock market and investing with confidence are common goals for new and old investors alike. Achieving those goals is made easier with the Zacks Style Scores, a unique set of guidelines that rates stocks based on popular investing methodologies, namely value, growth, and momentum. The Style Scores can help you narrow down which stocks are better for your portfolio and which ones can beat the market over the long-term. Why Investors Should Pay Attention to This Value Stock Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks. Fresenius (FMS) Based in Bad Homburg, Germany, Fresenius Medical Care AG & Co. KGaA is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. FMS sits at a Zacks Rank #1 (Strong Buy), holds a Value Style Score of B, and has a VGM Score of B. Compared to the Medical - Instruments industry's P/E of 26.9X, shares of Fresenius are trading at a forward P/E of 12.6X. FMS also has a PEG Ratio of 0.7, a Price/Cash Flow ratio of 5.7X, and a Price/Sales ratio of 0X. High Yield Savings Offers Earn 4.10% APY** on balances of $5,000 or more View Offer Earn up to 4.00% APY with Savings Pods View Offer Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit View Offer Powered by Money.com - Yahoo may earn commission from the links above. A company's earnings performance is important for value investors as well. For fiscal 2025, five analysts revised their earnings estimate higher in the last 60 days for FMS, while the Zacks Consensus Estimate has increased $0.11 to $2.21 per share. FMS also holds an average earnings surprise of 6.6%. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding FMS to their portfolios. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 24.06.25 12:19:00 | FMS Stock Likely to Gain on New Optimization Plan FME Reignite | |
| Fresenius Medical Care FMS recently unveiled its forward-looking “FME Reignite” strategy at the 2025 Capital Markets Day, aiming to achieve industry-leading profitability while optimizing capital structure and advancing innovation in renal care. This comprehensive plan builds on the momentum of its prior transformation initiatives and integrates a sharp focus on capital returns, technological leadership and organizational agility. Strengthening Profitability Through FME25+ and Operational Focus At the heart of the FME Reignite strategy lies an aggressive expansion of the existing FME25 program, now rebranded as FME25+, targeting €1.05 billion in sustainable cost savings by 2027. This €300 million increase over prior goals reflects the company’s focus on operational excellence and margin expansion. These savings are expected to be channeled directly into margin improvement, helping FMS achieve its mid-teens operating income margin target by 2030 across both its Care Delivery and Care Enablement segments. By establishing Value-Based Care (“VBC”) as a standalone segment, Fresenius enhances transparency and strategic clarity. Having generated €1.8 billion in 2024 revenues, this business unit is built around long-term partnerships with both public and private payors in the United States, aiming to deliver better outcomes at lower costs. The VBC model aligns well with broader healthcare trends favoring preventive, personalized care and is expected to become a material contributor to Fresenius’ growth and resilience. FME25+ not only supports profitability but also enhances scalability, standardization, and efficiency across clinics and manufacturing sites. As a vertically integrated player, Fresenius is well-positioned to leverage synergies across its operating arms to streamline service delivery while maintaining care quality.Fresenius Medical Care Image Source: Fresenius Medical Care Capital Structure Optimization and Shareholder Value Creation A key pillar of the strategy is a new capital allocation framework designed to balance reinvestment and shareholder returns. Fresenius plans to allocate €800 million to €1 billion annually for capital expenditures through 2030, reinforcing its innovation pipeline and core operations. Simultaneously, it aims to reduce its net financial leverage to a more conservative 2.5X-3.0X range, down from the earlier 3.0X-3.5X target, demonstrating a prudent approach amid macroeconomic uncertainties. To return value to shareholders, Fresenius will initiate a €1 billion share buyback program over two years beginning in 2025 and has committed to a dividend payout ratio of 30-40%. This dual-pronged return strategy underscores a clear intent to enhance investor confidence while maintaining financial flexibility. Story Continues Fresenius Medical Care Image Source: Fresenius Medical Care Technological Advancement: 5008X and Hemodiafiltration as a New Standard Another cornerstone of the strategy is the upcoming U.S. commercial launch of the 5008X CAREsystem, Fresenius’s next-generation dialysis machine. The FDA-cleared 5008X enables high-volume hemodiafiltration (HVHDF), a modality that has demonstrated significant survival and quality-of-life benefits compared to conventional hemodialysis. Backed by the CONVINCE study, HVHDF showed a 4.4% mortality reduction over 2.5 years and promises lower hospitalization and improved treatment consistency. Fresenius plans to replace all 2008T machines in its U.S. clinics with the 5008X by 2030, driving not only clinical outcomes but also operational efficiencies such as reduced clinic labor and drug use. With its market-leading installed base and exclusive FDA clearance, the company also expects to expand its market share in disposables tied to this platform. FMS vs Competing Companies Through FME Reignite, Fresenius Medical Care is repositioning itself as a financially disciplined, innovation-driven, and patient-centered leader in renal care. By combining cost control with growth investments, optimizing capital allocation, and advancing clinical standards, the company is set to unlock meaningful long-term value for patients and shareholders alike. Baxter International BAX, DaVita Inc. DVA and Outset Medical OM are also navigating profitability and capital strategies through distinct lenses shaped by their business models and market positions. Baxter, having divested its kidney care business, is now focused on rebuilding profitability across its hospital and digital health portfolios. The company has improved gross margins through cost controls and is deleveraging its balance sheet following recent spin-offs. Capital allocation remains disciplined,with a renewed focus on organic investments and debt reduction. In contrast, DaVita, a pure-play dialysis provider, maintains stable operating margins through scale efficiencies and disciplined cost management. DVA’s profit sharing strategy depends heavily on share buybacks. The company recently issued senior notes worth $1 billion, reflecting a high-leverage model focused on returning capital to shareholders. Meanwhile, Outset Medical, a younger player, is prioritizing margin improvement and cash burn reduction. While still unprofitable, OM has improved gross margins to ~37% and is narrowing its losses through cost discipline and operational streamlining. However, Outset Medical remains reliant on external funding, often through dilutive equity raises. Shares of FMS have outperformed its industry as well as its peers. The company’s shares have risen 19.8% year to date against the industry’s decline of 12%. While shares of BAX and OM have gained 2.8% and 4.3%, respectively, in the same period, those of DVA have lost 8.9%. The S&P 500 Index has increased 0.8% in the same time frame. YTD Performance ChartZacks Investment Research Image Source: Zacks Investment Research Fresenius Medical currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Baxter International Inc. (BAX) : Free Stock Analysis Report DaVita Inc. (DVA) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Outset Medical, Inc. (OM) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 23.06.25 06:00:00 | Opterion Health AG Appoints Industry Leaders Rice Powell and Mark Hahn to Board of Directors | |
| Opterion Health AG MUTTENZ, Switzerland, June 23, 2025 (GLOBE NEWSWIRE) -- Opterion Health AG, a Swiss-based life sciences company developing a next-generation, non-glucose based peritoneal dialysis (PD) solution, today announced the appointment of two highly accomplished executives to its Board of Directors: Rice Powell, former Chairman and CEO of Fresenius Medical Care, and Mark Hahn, Chief Financial Officer of Verona Pharma and a veteran biotech finance leader. These appointments represent a significant step forward in the strategic development of Opterion Health as it prepares for clinical trials and future commercialization. Rice Powell and Mark Hahn have demonstrated decades of leadership in renal care, biotechnology, and corporate strategy, reinforcing the company’s commitment to innovation and improving patient outcomes. Rice Powell brings more than 30 years of experience in the global dialysis and healthcare industry. As Chairman and CEO of Fresenius Medical Care, he led the world’s largest provider of dialysis products and services through a decade of strategic transformation and international growth. His leadership was instrumental in expanding access to renal therapies and improving standards of care across continents.Rice_Powell_image Rice Powell, Former Chairman and CEO of Fresenius Medical Care “The mission of Opterion Health to transform peritoneal dialysis resonates deeply with me,” said Rice Powell. “Having spent my career focused on renal care, I see tremendous potential in this approach to improving quality of life for patients. I’m honored to support the company’s vision and contribute to its strategic direction.” Mark Hahn brings over two decades of financial leadership in the life sciences sector. Currently serving as CFO of Verona Pharma, he has played a central role in fundraising, IPO execution, and scaling operations in both private and public biotech companies. His previous roles include CFO positions at Dova Pharmaceuticals, Cempra, and Athenix, where he consistently delivered financial strategy aligned with corporate growth.Mark_Hahn_image Mark Hahn, Chief Financial Officer of Verona Pharma Mark Hahn also works closely with David Ebsworth, Chairman of Opterion Health, at Verona Pharma. Their ongoing collaboration and shared experience navigating complex financial and regulatory environments will be instrumental as Opterion Health advances its clinical and commercial roadmap. “Opterion Health is at a truly exciting inflection point,” said Mark Hahn. “The science is compelling, the leadership is visionary, and the opportunity to make a real difference in patients’ lives is profound. I’m excited to help guide the company’s financial and strategic growth.” Story Continues David Ebsworth commented: “Welcoming Rice and Mark to our Board is a major milestone for Opterion Health. Rice’s unparalleled leadership in renal care and Mark’s deep financial expertise bring extraordinary strength to our governance. Their insights and experience will be invaluable as we move toward clinical trials and beyond. I am more confident than ever in the company’s future.” About Opterion Health AG Opterion Health is developing a novel peritoneal dialysis (PD) solution aimed at revolutionizing the dialysis market. Backed by leading life science investors, the company is headquartered in the Basel area, the pharmaceutical heart of Switzerland, and supported by a strong team of scientists, entrepreneurs, and nephrologists across Europe. Find us at: www.opterion.com Photos accompanying this announcement are available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/9eeb9d50-acc3-40fc-b60c-19bef6e304e7https://www.globenewswire.com/NewsRoom/AttachmentNg/e5b8d242-9b25-4ace-8890-b367b1c4fb04 For more information or to contact us, please email info@opterion.com View Comments |
||
| 22.06.25 07:21:25 | Are Poor Financial Prospects Dragging Down Fresenius Medical Care AG (ETR:FME Stock? |  |
| With its stock down 9.1% over the past month, it is easy to disregard Fresenius Medical Care (ETR:FME). We decided to study the company's financials to determine if the downtrend will continue as the long-term performance of a company usually dictates market outcomes. Particularly, we will be paying attention to Fresenius Medical Care's ROE today. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors’ money. In short, ROE shows the profit each dollar generates with respect to its shareholder investments. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. How To Calculate Return On Equity? Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Fresenius Medical Care is: 5.2% = €812m ÷ €16b (Based on the trailing twelve months to March 2025). The 'return' is the amount earned after tax over the last twelve months. So, this means that for every €1 of its shareholder's investments, the company generates a profit of €0.05. Check out our latest analysis for Fresenius Medical Care What Has ROE Got To Do With Earnings Growth? We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes. A Side By Side comparison of Fresenius Medical Care's Earnings Growth And 5.2% ROE When you first look at it, Fresenius Medical Care's ROE doesn't look that attractive. However, given that the company's ROE is similar to the average industry ROE of 5.1%, we may spare it some thought. But Fresenius Medical Care saw a five year net income decline of 21% over the past five years. Bear in mind, the company does have a slightly low ROE. Hence, this goes some way in explaining the shrinking earnings. However, when we compared Fresenius Medical Care's growth with the industry we found that while the company's earnings have been shrinking, the industry has seen an earnings growth of 16% in the same period. This is quite worrisome.XTRA:FME Past Earnings Growth June 22nd 2025 The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Fresenius Medical Care fairly valued compared to other companies? These 3 valuation measures might help you decide. Story Continues Is Fresenius Medical Care Using Its Retained Earnings Effectively? With a high three-year median payout ratio of 55% (implying that 45% of the profits are retained), most of Fresenius Medical Care's profits are being paid to shareholders, which explains the company's shrinking earnings. With only a little being reinvested into the business, earnings growth would obviously be low or non-existent. Moreover, Fresenius Medical Care has been paying dividends for at least ten years or more suggesting that management must have perceived that the shareholders prefer dividends over earnings growth. Upon studying the latest analysts' consensus data, we found that the company's future payout ratio is expected to drop to 39% over the next three years. As a result, the expected drop in Fresenius Medical Care's payout ratio explains the anticipated rise in the company's future ROE to 8.3%, over the same period. Summary On the whole, Fresenius Medical Care's performance is quite a big let-down. Because the company is not reinvesting much into the business, and given the low ROE, it's not surprising to see the lack or absence of growth in its earnings. With that said, we studied the latest analyst forecasts and found that while the company has shrunk its earnings in the past, analysts expect its earnings to grow in the future. To know more about the company's future earnings growth forecasts take a look at this freereport on analyst forecasts for the company to find out more. — Weekly Picks from Community Investing narratives with Fair Values Vita Life Sciences Set for a 12.72% Revenue Growth While Tackling Operational Challenges By Robbo – Community Contributor Fair Value Estimated: A$2.42 · 0.1% Overvalued Vossloh rides a €500 billion wave to boost growth and earnings in the next decade By Chris1 – Community Contributor Fair Value Estimated: €78.41 · 0.1% Overvalued Intuitive Surgical Will Transform Healthcare with 12% Revenue Growth By Unike – Community Contributor Fair Value Estimated: $325.55 · 0.6% Undervalued View more featured narratives — Have feedback on this article? Concerned about the content?Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. View Comments |
||
| 17.06.25 16:33:00 | Health Care Roundup: Market Talk | |
| Find insight on Hinge Health, Fresenius Medical Care and more in the latest Market Talks covering Health Care. Continue Reading View Comments |
||
| 17.06.25 12:56:00 | Fresenius Medical Care CEO Says Company Could Benefit From Obesity Drugs | |
| EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive’ rather than negative. Continue Reading |
||
| 04.06.25 16:31:00 | Reasons to Add Fresenius Medical Stock to Your Portfolio Now | |
| Fresenius Medical Care AG & Co. FMS is well-poised for growth on the back of strategic acquisitions and partnerships and a solid global foothold. However, a tough regulatory environment remains a concern. Shares of this Zacks Rank #2 (Buy) company have risen 25.1% year to date against the industry’s decline of 9.1%. The S&P 500 Index has increased 0.9% in the same time frame. The company, with a market capitalization of $16.64 billion, is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Its bottom line is anticipated to improve 9.6% over the next five years. FMS’ earnings beat estimates in all the trailing four quarters, delivering an average surprise of 6.6%.Zacks Investment Research Image Source: Zacks Investment Research Reasons Favoring FMS’s Growth Strategic Acquisitions & Partnerships: Fresenius Medical has leveraged strategic acquisitions and partnerships to drive its growth strategy. It acquired NxStage Medical for $30 per share, expecting earnings accretion within three years and annual pre-tax savings of $80 million to $100 million. The company’s 2025 growth strategy includes the merger of Fresenius Health Partners, InterWell Health, and Cricket Health to manage 270,000 patients with kidney disease and $11 billion in associated medical costs. Additionally, it expanded its home dialysis market through a distribution deal with JMS Co. Ltd. in Japan and extended agreements with DaVita and Aetna to enhance patient access to home hemodialysis and value-based care. Strong Global Foothold: Fresenius Medical has a strong global presence across North America, Europe (EMEA), the Asia Pacific, and Latin America, expanding through organic growth and strategic acquisitions. It entered the dialysis market in Israel and strengthened its foothold in India by acquiring an 85% stake in Sandor Nephro Services. The company also focuses on public-private partnerships to tap into new markets. Despite pandemic challenges, it has maintained steady organic growth, with significant contributions from EMEA, Asia Pacific, and Latin America, particularly in the third quarter of 2024. Strong Q1 Results: FMS exited the first quarter on a mixed note, with its earnings and revenues surpassing and missing their respective Zacks Consensus Estimate. Overall pricing momentum also supported growth in the Care Enablement segment. Per management, during the first quarter, the FME25 transformation program continued its positive momentum, delivering EUR 68 million additional sustainable savings while related one-time costs, treated as special items, amounted to EUR 28 million. The company confirmed its full-year target of around EUR 180 million in additional annual savings, totaling EUR 750 million by 2025-end. Story Continues The company’s continued divestment of its non-core and dilutive assets appears promising, as it will help focus on its core and growing categories, while also boosting its cash resources. A Factor That May Offset FMS’s Gains Tough Regulatory Environment: Fresenius Medical operates in a highly regulated environment, facing strict legal and antitrust requirements across countries. Non-compliance can result in severe penalties, loss of certifications, product recalls, or even business restrictions. Regulatory changes, especially in reimbursement policies, could impact its business model and strategy. Additionally, international exposure presents challenges in enforcing trade receivables, with some countries' debt issues posing potential risks. While short-term regulatory risks remain low, they could become a medium-term concern. Estimate Trend The Zacks Consensus Estimate for 2025 revenues is pegged at $21.84 billion, indicating 4.4% year-over-year growth. The consensus mark for earnings is pinned at $2.16 per share, implying growth of 30.1% from the year-ago level. The earnings estimates have improved 15 cents in the past 90 days. Other Key Picks Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2, reported first-quarter 2025 adjusted EPS of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite’s 10.5% growth. AngioDynamics’ earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 02.06.25 13:50:08 | Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio | |
| It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Many investors also have a go-to methodology that helps guide their buy and sell decisions. One way to find winning stocks based on your preferred way of investing is to use the Zacks Style Scores, which are indicators that rate stocks based on three widely-followed investing types: value, growth, and momentum. Is This 1 Momentum Stock a Screaming Buy Right Now? For momentum investors, upward or downward trends in a stock's price or earnings outlook take precedent, so they'll want to zero in on the Momentum Style Score. This Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates. Fresenius (FMS) Based in Bad Homburg, Germany, Fresenius Medical Care AG & Co. KGaA is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. FMS sits at a Zacks Rank #3 (Hold), holds a Momentum Style Score of A, and has a VGM Score of A. The stock is down 2.1% and up 11% over the past one-week and four-week period, respectively, and Fresenius has gained 33.5% in the last one-year period as well. Additionally, an average of 578,519.88 shares were traded over the last 20 trading sessions. Advertisement: High Yield Savings Offers Earn 4.10% APY** on balances of $5,000 or more View Offer Earn up to 4.00% APY with Savings Pods View Offer Earn up to 3.80% APY¹ & up to $300 Cash Bonus with Direct Deposit View Offer Powered by Money.com - Yahoo may earn commission from the links above. A company's earnings performance is important for momentum investors as well. For fiscal 2025, four analysts revised their earnings estimate higher in the last 60 days for FMS, while the Zacks Consensus Estimate has increased $0.05 to $2.16 per share. FMS also boasts an average earnings surprise of 6.6%. FMS should be on investors' short list because of its impressive earnings fundamentals, a good Zacks Rank, and strong Momentum and VGM Style Scores. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research View Comments |
||
| 15.05.25 12:06:00 | 5 High-Flying Medical Instrument Stocks to Buy Despite Recent Turmoil | |
| The medical instruments industry is currently undergoing a transformative phase, thanks to the rapid adoption of generative artificial intelligence (genAI) and digital therapeutics, which market watchers expect will take the healthcare industry by storm. Since the beginning of 2023, the industry has been witnessing mass adoption of AI and the Internet of Medical Things in the form of digital healthcare options in hospitals and other healthcare settings. GenAI has begun to showcase its proficiency across a range of healthcare fields, from time-consuming administrative tasks to critical areas such as technological discovery and clinical trials. GenAI, while analyzing vast and complex genetic and molecular data, is expected to help healthcare reach new heights in terms of predictive treatment options and smart hospital systems. At this stage, it should be prudent to invest in stocks from the Zacks-defined Medical Instrument industry with a favorable Zacks Rank. We have selected five such stocks that have provided double-digit returns in the past month during which Wall Street suffered severe volatility. These stocks are: DexCom Inc. DXCM, IDEXX Laboratories Inc. IDXX, NeuroPace Inc. NPCE, Fresenius Medical Care AG FMS and ClearPoint Neuro Inc. CLPT. Each of our picks carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The chart below shows the price performance of our five picks in the past month.Zacks Investment Research Image Source: Zacks Investment Research DexCom Inc. DexCom has benefited from an impressive contribution from the Sensor segment and domestic and international revenue growth have acted as the key catalysts. DXCM’s prospects with Stelo as an OTC monitor for type 2 diabetes bode well. DXCM made continued advancements concerning key strategic objectives and ended the quarter with new patient additions. DXCM’s slew of tie-ups with AID systems is encouraging. A solid international foothold and robust product portfolio augur well. A strong solvency position is an added plus. DexCom has an expected revenue and earnings growth rate of 14.3% and 23.2%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.5% over the last 60 days. IDEXX Laboratories Inc. IDEXX Laboratories’ robust strategic execution is highlighted by new business gains, high customer retention levels and solid net price realization. This underscores the consistent growth in the CAG international business, supported by volume gains and global premium instrument placements. Story Continues IDXX’s software solutions are facilitating growth by enhancing clinic workflows and promoting greater utilization of diagnostics. Also, the consumable business boosts IDXX’s top line. IDXX is focused on growing its global commercial capability to sustain strong CAG Diagnostics recurring revenue growth. IDEXX Laboratories has an expected revenue and earnings growth rate of 5.8% and 14%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 0.4% over the last seven days. NeuroPace Inc. NeuroPace operates as a medical device company in the United States. NPCE develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. NPCE’s RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, NPCE provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. NPCE sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace has an expected revenue and earnings growth rate of 18.1% and 15.1%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 12.2% over the last 60 days. Fresenius Medical Care AG Fresenius Medical Care has been benefiting from strong organic growth on the back of improving treatment volumes as well as a stabilizing labor environment in the United States. Continued improvement in these two key factors should be beneficial for FMS in 2025. Overall pricing momentum also supported growth in the Care Enablement segment. FMS’ newly implemented operating model led to operational improvements. FMS generated 221 million euros in savings in 2024 by implementing initiatives under the FME25 transformation program. FMS’ continued divestment of its noncore and dilutive assets seems promising. Fresenius Medical Care has an expected revenue and earnings growth rate of 1.6% and 28.3%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.4% over the last seven days. ClearPoint Neuro Inc. ClearPoint Neuro operates as a medical device company primarily in the United States. CLPT develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. CLPT offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. ClearPoint Neuro has an expected revenue and earnings growth rate of 24.1% and 11.4%, respectively, for the current year. The Zacks Consensus Estimate for current-year earnings has improved 1.6% over the last 30 days. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Fresenius Medical Care AG & Co. KGaA (FMS) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report IDEXX Laboratories, Inc. (IDXX) : Free Stock Analysis Report ClearPoint Neuro, Inc. (CLPT) : Free Stock Analysis Report NeuroPace, Inc. (NPCE) : Free Stock Analysis Report This article originally published on Zacks Investment Research (zacks.com). Zacks Investment Research |
||
